RxDoctor Payments Data

Nancy Bellinger, NP

Family · McDonough, GANPI 1770902124

Payments from drug & device makers

$655in general payments, 2019–2025

Across 28 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$343
  • Otsuka America Pharmaceutical, Inc.$68
  • AbbVie$56
  • Baxter Healthcare$51
  • Hologic Sales And Service, LLC$51
  • Vanda Pharmaceuticals Inc.$25
  • plus $62 from 4 others

What the payments were for

  • Food & beverage$655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$655 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$82,425
Medicare patients
249
Services billed
2,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide309$337,976
JardianceEmpagliflozin109$139,061
MounjaroTirzepatide72$91,064
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$62,793
TrulicityDulaglutide37$36,364
Nurtec OdtRimegepant Sulfate23$33,361
EliquisApixaban22$25,489
RybelsusSemaglutide20$20,917
LinzessLinaclotide25$19,063
JanuviaSitagliptin Phosphate17$18,209
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,428
Varenicline Tartrate31$8,606
SymbicortBudesonide/Formoterol Fumarate18$6,226
AirsupraAlbuterol Sulfate/Budesonide11$6,030
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$343$358,894329 claims
Boehringer IngelheimJardiance$16$139,061109 claims
Lilly USA, LLCMounjaro, Trulicity$13$127,429109 claims
AstraZenecaBreztri Aerosphere, Symbicort, Airsupra$15$21,68442 claims
AbbVieLinzess$56$19,06325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,258 family providers in Georgia.

Other family in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →